However, in melanoma, multiple studies revealed that PD-L1 expression in cancer cells correlated well with response to ICBs [11, 19, 20] and the FDA approved the 28-8 pharmDx assay as a complementary diagnostic for IHC detection of PD-L1 [21]. Here, CD274 is linked to melanoma.